AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25001306 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Number of subjects: 684
Study 25001306 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Number of subjects: 684
Study 22885290 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispreferred adjective orders
Number of subjects: 0
Study 22885290 — intervention group
Group type: COMPARATOR
Intervention: Preferred adjective orders
Number of subjects: 0
Study 19124057 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-OMPC formulations (3microg or 6microg)
Number of subjects: 708
Study 19124057 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-T formulation (12microg)
Number of subjects: 708
Study 19124057 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccine formulations
Number of subjects: 708
Study 19124057 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulations
Number of subjects: 708
Study 19124057 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-OMPC formulations
Number of subjects: 708
Study 19124057 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-OMPC formulation with the lowest concentration
Number of subjects: 708
Study 18590622 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Mini-Mental State Examination (t‐MMSE)
Number of subjects: 141
Study 18590622 — intervention group
Group type: COMPARATOR
Intervention: In-person Mini-Mental State Examination (MMSE)
Number of subjects: 141
Study 16336480 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid Risk Tool (ORT)
Number of subjects: 185
Study 12020983 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol 2 mg+norethisterone acetate 1mg (E2+NETA) daily
Number of subjects: 133
Study 12020983 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene HCl 60 mg (Evista) daily
Number of subjects: 133
Study 12020983 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 133
Study 11783305 — intervention group
Group type: EXPERIMENTAL
Intervention: Juanxiao Tablet (JXT)
Number of subjects: 447
Study 11783305 — intervention group
Group type: COMPARATOR
Intervention: Oleum Vitex Negundo (Control)
Number of subjects: 447
Study 7540461 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (5 micrograms/Kg B.W.) administered after chemotherapy cycles as needed
Number of subjects: 20
Study 2186569 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (Blocalcin 60, Lachema)
Number of subjects: 13
Study 2186569 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (Isoket retard 120, Schwarz)
Number of subjects: 13
Study 2186569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 376883 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amphotericin B 50 mg four times a day
Number of subjects: 72
Study 376883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 31123810 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) for 24 weeks, 90-95% peak heart rate, 2 days per week
Number of subjects: 37
Study 31123810 — intervention group
Group type: COMPARATOR
Intervention: Usual care (CON)
Number of subjects: 37
Study 31123810 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 37
Study 28137523 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed yoga
Number of subjects: 0
Study 28137523 — intervention group
Group type: COMPARATOR
Intervention: Standard-speed yoga
Number of subjects: 0
Study 26343744 — intervention group
Group type: EXPERIMENTAL
Intervention: Debridement (CL-Deb)
Number of subjects: 190
Study 26343744 — intervention group
Group type: COMPARATOR
Intervention: Observation (CL-Obs)
Number of subjects: 190
Study 23433395 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard government school feeding programme
Number of subjects: 116
Study 23433395 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-grown school feeding and social accountability programme
Number of subjects: 116
Study 23433395 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed intervention)
Number of subjects: 116
Study 21251363 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment Maneuver (RM) group
Number of subjects: 38
Study 21251363 — intervention group
Group type: COMPARATOR
Intervention: Non-Recruitment Maneuver (non-RM) group
Number of subjects: 38
Study 21251363 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 38
Study 19038583 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium (100 mg)
Number of subjects: 12
Study 19038583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17205440 — intervention group
Group type: EXPERIMENTAL
Intervention: Miltefosine, 2.5 mg/kg/day for 28 days
Number of subjects: 72
Study 17205440 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B, 45 mg/kg over 90 days
Number of subjects: 72
Study 15622126 — intervention group
Group type: EXPERIMENTAL
Intervention: LF-ASD brain switch
Number of subjects: 2
Study 11338008 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive cardiac surgery (MICS)
Number of subjects: 48
Study 11338008 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiac surgery
Number of subjects: 48
Study 9376698 — intervention group
Group type: EXPERIMENTAL
Intervention: E153
Number of subjects: 74
Study 9376698 — intervention group
Group type: COMPARATOR
Intervention: Alcon BSS
Number of subjects: 74
Study 9376698 — intervention group
Group type: COMPARATOR
Intervention: Alcon BSS Plus
Number of subjects: 74
Study 9376698 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 74
Study 7890461 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restriction (ER) group (n = 16) received 80% of their habitual energy intake for ten weeks
Number of subjects: 24
Study 7890461 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restriction (ER) group (n = 16)
Number of subjects: 24
Study 7890461 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 8) received weight-maintaining diet for ten weeks
Number of subjects: 24
Study 3065355 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of mifepristone
Number of subjects: 35
Study 3065355 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg of mifepristone
Number of subjects: 35
Study 29136682 — intervention group
Group type: EXPERIMENTAL
Intervention: CCC Workshop
Number of subjects: 84
Study 29136682 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 84
Study 28877312 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluorouracil, 5%, cream applied twice daily for 2 to 4 weeks (28 to 56 doses)
Number of subjects: 281
Study 28877312 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control cream applied twice daily for 2 to 4 weeks (28 to 56 doses)
Number of subjects: 281
Study 28877312 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluorouracil, 5%, cream
Number of subjects: 281
Study 28877312 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control cream
Number of subjects: 281
Study 26598079 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide contrast medium
Number of subjects: 21
Study 26598079 — intervention group
Group type: COMPARATOR
Intervention: Iodine contrast medium
Number of subjects: 21
Study 23578589 — intervention group
Group type: EXPERIMENTAL
Intervention: Selling cigarettes (loosies)
Number of subjects: 801
Study 23578589 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing street security
Number of subjects: 801
Study 23578589 — intervention group
Group type: EXPERIMENTAL
Intervention: Selling food stamps
Number of subjects: 801
Study 23578589 — intervention group
Group type: EXPERIMENTAL
Intervention: Pawning items
Number of subjects: 801
Study 23578589 — intervention group
Group type: EXPERIMENTAL
Intervention: Selling drugs
Number of subjects: 801
Study 21149743 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic messages highlighting overdue screening status with a link to a Web-based risk assessment tool.
Number of subjects: 1103
Study 21149743 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic messages highlighting overdue screening status with a link to a Web-based risk assessment tool (among those who viewed the message).
Number of subjects: 1103
Study 21149743 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk assessment tool users.
Number of subjects: 1103
Study 18665117 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 40
Study 18665117 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 40
Study 16788295 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity Index (AI(ADL))
Number of subjects: 75
Study 16788295 — intervention group
Group type: EXPERIMENTAL
Intervention: Barthel Index (BI)
Number of subjects: 75
Study 16788295 — intervention group
Group type: COMPARATOR
Intervention: Barthel Index (BI) and Activity Index (AI(ADL))
Number of subjects: 75
Study 12897732 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (estrogens, progestins, and their combination)
Number of subjects: 0
Study 12897732 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 11350672 — intervention group
Group type: EXPERIMENTAL
Intervention: Damp gauze (Group G)
Number of subjects: 10
Study 11350672 — intervention group
Group type: COMPARATOR
Intervention: Large‐tip cotton buds (Group C)
Number of subjects: 10
Study 9411409 — intervention group
Group type: COMPARATOR
Intervention: Impaired LV filling parameters (MV E/A 0.81 +/- 0.12)
Number of subjects: 74
Study 9411409 — intervention group
Group type: COMPARATOR
Intervention: Abnormal mitral flow parameters (MV E/A 0.72 +/- 0.15)
Number of subjects: 74
Study 9411409 — intervention group
Group type: COMPARATOR
Intervention: Abnormal tricuspid flow parameters (TV E/A 0.8 +/- 0.19)
Number of subjects: 74
Study 9411409 — intervention group
Group type: COMPARATOR
Intervention: Impaired diastolic filling of both ventricles (MV E/A 0.72 +/- 0.15)
Number of subjects: 74
Study 9411409 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between TV A and MV E
Number of subjects: 74
Study 9411409 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between MV E-VTI
Number of subjects: 74
Study 9411409 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between MV A
Number of subjects: 74
Study 9411409 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between LV mass and TV E
Number of subjects: 74
Study 9411409 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between time velocity integral of early tricuspid inflow
Number of subjects: 74
Study 1305312 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 300 mg b.i.d.
Number of subjects: 61
Study 1305312 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg/day plus placebo
Number of subjects: 61
Study 3906106 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone treatment (100 mg twice daily delivered in vaginal pessaries)
Number of subjects: 15
Study 3906106 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 15
Study 31647280 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 IU intranasal insulin
Number of subjects: 30
Study 31647280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29454255 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL)
Number of subjects: 123
Study 29454255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 26855018 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (glucagon‐like peptide‐1 receptor agonist)
Number of subjects: 9340
Study 26855018 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior CVD
Number of subjects: 9340
Study 26855018 — intervention group
Group type: EXPERIMENTAL
Intervention: Residency in North America
Number of subjects: 9340
Study 24356862 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring-based dose adaptation strategy
Number of subjects: 41
Study 24356862 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 41
Study 21851293 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified constraint-induced movement therapy (modified CIMT) at home (n=7)
Number of subjects: 14
Study 21851293 — intervention group
Group type: COMPARATOR
Intervention: Modified constraint-induced movement therapy (modified CIMT) at clinic (n=7)
Number of subjects: 14
Study 20417856 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mg liraglutide
Number of subjects: 665
Study 20417856 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mg liraglutide
Number of subjects: 665
Study 20417856 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin (100 mg)
Number of subjects: 665
Study 20417856 — intervention group
Group type: COMPARATOR
Intervention: 1.8 mg liraglutide vs Sitagliptin
Number of subjects: 665
Study 20417856 — intervention group
Group type: COMPARATOR
Intervention: 1.2 mg liraglutide vs Sitagliptin
Number of subjects: 665
Study 20417856 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (both doses)
Number of subjects: 665
Study 20417856 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 665
Study 18500610 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (1.0 MAC)
Number of subjects: 44
Study 18500610 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (1.0 MAC)
Number of subjects: 44
Study 15694949 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin, 40 mg daily
Number of subjects: 568
Study 15694949 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (physical activity and diet)
Number of subjects: 568
Study 15694949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 568
Study 12672708 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole tablet dietary supplement
Number of subjects: 15
Study 12672708 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed tablet dietary supplement
Number of subjects: 15
Study 12672708 — intervention group
Group type: COMPARATOR
Intervention: Test meal alone (control)
Number of subjects: 15
Study 12672708 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal permeability influence on vitamin B(12)
Number of subjects: 15
Study 10881002 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin (DNR) 25 mg/m(2), i.v., weekly, x4 (cumulative dose 100 mg/m(2))
Number of subjects: 90
Study 10881002 — intervention group
Group type: COMPARATOR
Intervention: No daunorubicin (DNR)
Number of subjects: 90
Study 8567951 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern of viral replication (rapid increase in plasma viral RNA and cell-associated proviral DNA)
Number of subjects: 11
Study 8567951 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern of viral replication (initial rapid increase followed by a decline in viral levels)
Number of subjects: 11
Study 8567951 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern of viral replication (significantly lower viral increase)
Number of subjects: 11
Study 1571905 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated superfractionated radiation therapy using a concomitant boost twice‐a‐day schedule (BID); 180 cGy/fraction with a boost of 160 cGy/fraction BID, 3 days per week.
Number of subjects: 100
Study 1571905 — intervention group
Group type: COMPARATOR
Intervention: Conventional once‐a‐day (QD) fractionation to doses in excess of 6600 cGy.
Number of subjects: 100
Study 6363727 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide
Number of subjects: 668
Study 6363727 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 668
Study 30401610 — intervention group
Group type: EXPERIMENTAL
Intervention: 24,000 IU vitamin D3/mo
Number of subjects: 200
Study 30401610 — intervention group
Group type: EXPERIMENTAL
Intervention: 60,000 IU vitamin D3/mo
Number of subjects: 200
Study 30401610 — intervention group
Group type: EXPERIMENTAL
Intervention: 24,000 IU vitamin D3 plus 300 μg calcifediol/mo
Number of subjects: 200
Study 29414988 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover feet (XF)
Number of subjects: 27
Study 27009179 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatially targeted vaccination (80% of adults in hotspots)
Number of subjects: 100000
Study 27009179 — intervention group
Group type: COMPARATOR
Intervention: Untargeted vaccination (8% of adults in general population)
Number of subjects: 100000
Study 25257928 — intervention group
Group type: EXPERIMENTAL
Intervention: Early External Cephalic Version (EECV)
Number of subjects: 0
Study 25257928 — intervention group
Group type: COMPARATOR
Intervention: Delayed External Cephalic Version (EECV)
Number of subjects: 0
Study 22512265 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg/day)
Number of subjects: 40
Study 22512265 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide (5 mg/day)
Number of subjects: 40
Study 20615746 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived neighborhood characteristics (children do not play outdoors, neighborhood well lit, presence of trails)
Number of subjects: 0
Study 20615746 — intervention group
Group type: COMPARATOR
Intervention: Neighborhood or transportation measures
Number of subjects: 0
Study 18042032 — intervention group
Group type: COMPARATOR
Intervention: 10 mL of 2% lidocaine gel intrarectally 10 minutes before biopsy
Number of subjects: 62
Study 18042032 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of intrarectal 40% DMSO with lidocaine equal to that in the lidocaine gel 10 minutes before procedure
Number of subjects: 62
Study 11213851 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine chewable dispersible tablets administered rectally
Number of subjects: 12
Study 11213851 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine chewable dispersible tablets administered orally
Number of subjects: 12
Study 9278079 — intervention group
Group type: EXPERIMENTAL
Intervention: AO 3.5‐millimeter cannulated screw
Number of subjects: 2
Study 9278079 — intervention group
Group type: EXPERIMENTAL
Intervention: Acutrak cannulated screw
Number of subjects: 2
Study 9278079 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbert‐Whipple screw
Number of subjects: 2
Study 9278079 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal Compression screw
Number of subjects: 2
Study 9278079 — intervention group
Group type: COMPARATOR
Intervention: Herbert screw
Number of subjects: 2
Study 9278079 — intervention group
Group type: EXPERIMENTAL
Intervention: AO screw and Herbert screw (in a separate setup)
Number of subjects: 2
Study 8101813 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin (20 micrograms, nasal spray, daily for 28 days)
Number of subjects: 59
Study 8101813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 8101813 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin
Number of subjects: 59
Study 8101813 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 59
Study 3461193 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer screening
Number of subjects: 0
Study 29441424 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitors (SSRIs)
Number of subjects: 1138
Study 29441424 — intervention group
Group type: COMPARATOR
Intervention: Non-users of SSRIs
Number of subjects: 1138
Study 27501953 — intervention group
Group type: EXPERIMENTAL
Intervention: Flapless (FLS) immediate implant placement
Number of subjects: 39
Study 27501953 — intervention group
Group type: COMPARATOR
Intervention: Flap-involving (F) immediate implant placement
Number of subjects: 39
Study 24334800 — intervention group
Group type: EXPERIMENTAL
Intervention: PIVC inserted in hand, antecubital fossa, or upper arm
Number of subjects: 3283
Study 24334800 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger diameter PIVC
Number of subjects: 3283
Study 24334800 — intervention group
Group type: EXPERIMENTAL
Intervention: PIVC inserted by operating and radiology suite staff
Number of subjects: 3283
Study 24334800 — intervention group
Group type: EXPERIMENTAL
Intervention: PIVC inserted in hand or antecubital fossa
Number of subjects: 3283
Study 24334800 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical staff insertion
Number of subjects: 3283
Study 24334800 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller PIVC diameter
Number of subjects: 3283
Study 24334800 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 3283
Study 23271103 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin levels greater than 15 µU/mL
Number of subjects: 160
Study 23271103 — intervention group
Group type: COMPARATOR
Intervention: Insulin levels of 5 µU/mL to 15 µU/mL
Number of subjects: 160
Study 23271103 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors
Number of subjects: 160
Study 23271103 — intervention group
Group type: COMPARATOR
Intervention: Nonsurvivors
Number of subjects: 160
Study 23271103 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 160
Study 23271103 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis patients
Number of subjects: 160
Study 20622608 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS-derived StO2
Number of subjects: 147
Study 18274807 — intervention group
Group type: COMPARATOR
Intervention: Volumetric MRI measures (T(1)-weighted scans)
Number of subjects: 52
Study 18274807 — intervention group
Group type: COMPARATOR
Intervention: Cognitive tests including MMSE, AD Assessment Scale-Cognitive Subscale, Disability Assessment for Dementia, AD Cooperative Study-Clinical Global Impression of Change, Clinical Dementia Rating
Number of subjects: 52
Study 16183735 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct observation by health facility workers
Number of subjects: 32
Study 16183735 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct observation by community health workers
Number of subjects: 32
Study 16183735 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct observation by family members
Number of subjects: 32
Study 16183735 — intervention group
Group type: COMPARATOR
Intervention: Self-administered treatment (control group)
Number of subjects: 32
Study 16183735 — intervention group
Group type: EXPERIMENTAL
Intervention: In-depth interviews with patients
Number of subjects: 32
Study 16183735 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall TB care approach
Number of subjects: 32